Skip to content
Showing 71 - 80 of 1498 results.
Dr. Jeffrey Lieberman’s concerns about whether dosing strategies for ketamine have been properly set by clinical trials are mentioned in this Q&A.
Dr. Paul S. Appelbaum and colleague examine the multiple changes looming in both the doctor’s and the patient’s roles in the move toward precision medicine.
“Going from not knowing each other to identifying shared interests is one of the first steps in making new friends and apps, online communities, the internet can fast track that,” Dr. Ali Mattu said.
When the drug works, its effect is almost immediate. That speed “is a huge thing because depressed patients are very disabled and suffer enormously,” said Dr. John Mann.
Dr. Alan S. Brown, said that "overall, the investigators have done a commendable job." However, he also noted that the "findings could also be influenced by treatment-seeking behaviors."
“Approval of esketamine is important for patients because other options like transcranial magnetic stimulation work more poorly in medication-resistant depression,” writes Dr. J. John Mann.
“This is undeniably a major advance,” said Dr. Jeffrey Lieberman. But he cautioned much is still unknown about the drug, particularly regarding its long-term use.
The FDA is set to approve SPRAVATOTM, an esketamine nasal spray that could help certain patients with severe depression. Dr. Drew Ramsey explains.
The test could give parents false hope about quick answers for their child’s diagnosis — and, in doing so, prolong their path to the right answer, Dr. Jeremy Veenstra-VanderWeele says.
"I expect that clinicians will change their practices by prescribing fewer benzodiazepines and more antidepressants for people with schizophrenia," Dr. T. Scott Stroup said.